Patrys Limited (AU:PAB) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Patrys Limited reports a delay in the GMP manufacturing run of its cancer-targeting antibody drug PAT-DX1, due to a process inconsistency in specification testing at their Contract Development Manufacturing Organization. The issue is being addressed, with testing and potential drug release for clinical trials now expected in the second half of August 2024. This setback impacts the timeline for initiating clinical development for PAT-DX1, a promising treatment for various cancers.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
